Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT326 + BNT327 in advanced non-small cell lung cancer
CTR20254024Phase 2Active
- Sponsor
- BioNTech
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202, pumitamig in non-small cell lung cancer (NSCLC), sponsored by BioNTech. Started Dec 2025; status: active.
02
Drugs
YL202pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254024.